Call
+918447748545

Published on: Nov 13, 2020
2 minute read
By: Dr Rajan ( Medical Second Opinion Cell)

What Are Some Common Side Effects Of The COVID-19 Vaccine?

COVID Vaccine, the Pfizer update

On Monday Pfizer announced to the world the vaccine, once it has been developing with Germany's BioNTech, was found to be more than 90?fective. If this is substantiated, it may be possible for countries to receive the vaccine before the end of the year.

The Vaccine is an mRNA Vaccine, a novel method that introduces viral RNA into the body via a viral coat. The vaccine is incorporated into the person's cell, where the viral RNA is read and viral proteins are produced, including the coronavirus coat proteins. As the body reads and recognizes these proteins, it produces antibodies against these viral proteins and activates immune T cells against the virus.

The Pfizer results are based of a phase 3 clinical trial with 43, 538 participants with a diverse background. In this trial, the participants were split between those receiving a vaccine, and those who received a placebo with no effect. The vaccine is administered in two parts, with a 90?ficacy obtained 7 days after the second dose. This would mean a person is vaccinated just 28 days after the initial vaccination.

The FDA usually looks for a minimum 50?ficacy in vaccination when approving new vaccines. It may surprise you that the annual flu jab is also estimated to be 50?fective. The data from Pfizer was verified by an external, independent Data Monitoring Committee. It used data from 94 patients enrolled in the trial and subsequently developed COVID. It is from this groupset that 90% of efficacy is obtained. This is not the final data analysis, and further publications are expected in late November, with a potential FDA Emergency Use Authorisation approval if the data continues to show promise.

If approved, Pfizer has the ability to make 50 million shots before the end of the year, and 1.3 billion by the end of 2021. Many countries are clamoring for their fair share of these limited resources; the US has already negotiated 200m shots, UK 50m, and Germany (one of the major financers for the Pfizer vaccine) over 300m for European Countries.

We should emphasize that rapid vaccine development on this scale at this speed was unheard of prior to COVID. Usually, the animal studies for vaccines can take 1-2 years. In that time Pfizer and others have managed phase 1-3 clinical trials in humans, something that usually takes upwards of 10 years.

There are many unanswered questions that remain from this information.

How safe is the vaccine? Whilst safety information was not published, overall the vaccine appears to have minimal side effects. This is particularly difficult to state however since mRNA vaccines have never been used in people before.
Does the vaccine prevent transmission? In theory, yes. If you are immunized the replication of the virus should be limited significantly, so the number of viruses in each cough will be much lower. However, we do not have data to prove that there is no transmission, but that is also because we have very little data overall.
How long does the protection last? This is a very critical question. The 90?fectiveness rate was calculated just 7 days after the second shot, but it is likely this will change as data is collected over the long term. Some studies have suggested the antibody response fades within months following COVID infection. T Cell immunity on the other hand can stay for years, and it may be the effectiveness of creating a T cell immunity that dictates just how good this vaccine will be .

Read Blog

Monkeypox Virus Symptoms: Early Signs, Disease Progression, and When to Seek Care

Monkeypox, now commonly referred to as mpox, is a viral infection that has gained global attention due to outbreaks beyond traditionally affected regions. Understanding monkeypox virus symptoms is essential for early detection, timely isolation and prevention of further spread.

According to the World Health Organization and Indian public health authorities, awareness of symptom patterns plays a critical role in controlling outbreaks and protecting vulnerable populations.

What Is the Monkeypox Virus?

Monkeypox is caused by the monkeypox virus, a member of the Orthopoxvirus family, which also includes smallpox. While generally less severe than smallpox, monkeypox can still cause significant illness and discomfort.

The virus spreads primarily through close physical contact.

Incubation Period of Monkeypox

After exposure, symptoms typically appear within:

5 to 21 days
most commonly 6 to 13 days

Individuals may feel well during this period but can become infectious once symptoms begin.

Early Monkeypox Virus Symptoms

Fever

Fever is usually the first symptom and may be:

sudden in onset
moderate to high grade
accompanied by chills

Fever signals the start of systemic infection.

Headache and Body Aches

Patients often experience:

severe headache
muscle aches
back pain

These symptoms resemble many viral illnesses.

Fatigue and Weakness

Marked tiredness and low energy levels are common and may limit daily activities.

Swollen Lymph Nodes

Swollen lymph nodes are a distinguishing feature of monkeypox.

Common sites include:

neck
armpits
groin

This helps differentiate monkeypox from chickenpox or smallpox.

Development of Monkeypox Rash

The skin rash usually appears:

1 to 3 days after fever onset

It may begin on the face or genital area and spread to other parts of the body.

Stages of Monkeypox Rash

The rash progresses through well-defined stages:

Macules

Flat red spots on the skin.

Papules

Raised, firm bumps.

Vesicles

Fluid-filled blisters.

Pustules

Pus-filled lesions that are painful.

Scabs

Lesions crust over and eventually fall off.

Complete healing occurs once scabs detach.

Distribution of Rash

Rash commonly affects:

face
hands and feet
mouth
genital and anal areas

The number of lesions can vary widely.

Pain and Discomfort

Rash lesions may be:

painful
itchy during healing

Pain severity differs between individuals.

Other Possible Symptoms

Additional symptoms may include:

sore throat
cough
nasal congestion

These reflect upper respiratory involvement.

Duration of Illness

Monkeypox symptoms typically last:

2 to 4 weeks

Recovery occurs gradually as lesions heal.

Who Is at Higher Risk of Severe Illness?

Higher risk groups include:

children
pregnant women
individuals with weakened immunity
people with chronic illness

Early care is crucial in these groups.

Complications of Monkeypox

Though uncommon, complications may include:

secondary bacterial skin infections
dehydration
pneumonia
eye involvement

Prompt medical guidance reduces risk.

How Monkeypox Is Transmitted

Transmission occurs through:

direct skin-to-skin contact
contact with lesions or bodily fluids
respiratory droplets during close contact
contaminated clothing or bedding

Understanding transmission helps prevent spread.

When to Seek Medical Care

Seek medical evaluation if:

fever is followed by rash
lymph nodes become swollen
rash appears in genital or facial areas

Early diagnosis supports isolation and care.

Diagnosis and Testing

Diagnosis may involve:

clinical examination
laboratory testing of lesion samples

Public health authorities guide testing protocols.

Prevention and Control Measures

Preventive steps include:

avoiding close contact with infected individuals
maintaining good hand hygiene
isolating during illness
following public health guidance

Vaccination may be recommended for high-risk groups.

Role of Public Awareness

Awareness of symptoms:

enables early detection
reduces stigma
supports timely care

WHO emphasises community education in outbreak control.

Conclusion

Monkeypox virus symptoms typically begin with fever, body aches and swollen lymph nodes, followed by a characteristic rash that progresses through defined stages. While most cases are self-limiting, early recognition, medical evaluation and isolation are essential to prevent complications and reduce transmission. Staying informed and acting promptly protects both individual and public health.

References

World Health Organization (WHO) – Mpox (Monkeypox) Clinical and Public Health Guidance
Indian Council of Medical Research (ICMR) – Emerging Viral Infections Reports
National Centre for Disease Control (NCDC), India – Monkeypox Advisories
Lancet – Clinical Features and Outcomes of Mpox
NITI Aayog – Public Health Preparedness and Infectious Disease Control

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.